Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.
Follow-Up Questions
Who is the CEO of Adaptimmune Therapeutics PLC?
Mr. Adrian Rawcliffe is the Chief Executive Officer of Adaptimmune Therapeutics PLC, joining the firm since 2015.
What is the price performance of ADAP stock?
The current price of ADAP is $0.0683, it has decreased 65.86% in the last trading day.
What are the primary business themes or industries for Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC belongs to Biotechnology industry and the sector is Health Care
What is Adaptimmune Therapeutics PLC market cap?
Adaptimmune Therapeutics PLC's current market cap is $18.1M
Is Adaptimmune Therapeutics PLC a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Adaptimmune Therapeutics PLC, including 0 strong buy, 0 buy, 5 hold, 2 sell, and 0 strong sell
